Simultaneous cisplatin and radiation in endometrial adenocarcinoma cell lines.
The effects of concomitantly administered cisplatin and radiation were evaluated in four recently established endometrial adenocarcinoma cell lines. We used the 96-well clonogenic assay to obtain survival data which were fitted to the linear quadratic model. The area under the survival curve (AUC) was obtained by numerical integration. It turned out that there was only a systematic additive cytotoxic effect and no supra-additive, true radiosensitising effect could be found. The results were not affected by the cisplatin dose used, the intrinsic radiosensitivity of the cell lines or the sensitivity of the cells to cisplatin.
Rantanen
V
V
Department of Obstetrics and Gynecology, University of Turku, Finland.
Grénman
S
S
Kulmala
J
J
Grénman
R
R
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
D002945:Cisplatin